Literature DB >> 17351108

Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice.

Elizabeth S Raveche1, Erica Salerno, Brian J Scaglione, Vijaya Manohar, Fatima Abbasi, Yi-Chu Lin, Torgny Fredrickson, Pablo Landgraf, Sumant Ramachandra, Konrad Huppi, Jorge R Toro, Vincent E Zenger, Robert A Metcalf, Gerald E Marti.   

Abstract

New Zealand black (NZB) mice with autoimmune and B lymphoproliferative disease (B-LPD) are a model for human chronic lymphocytic leukemia (CLL). A genomewide linkage scan of the NZB loci associated with lymphoma was conducted in F1 backcrosses of NZB and a control strain, DBA/2. Of 202 mice phenotyped for the presence or absence of LPD, surface maker expression, DNA content, and microsatellite polymorphisms, 74 had disease. The CD5(+), IgM(+), B220(dim), hyperdiploid LPD was linked to 3 loci on chromosomes 14, 18, and 19 that are distinct from previously identified autoimmunity-associated loci. The region of synteny with mouse D14mit160 is the human 13q14 region, associated with human CLL, containing microRNAs mir-15a16-1. DNA sequencing of multiple NZB tissues identified a point mutation in the 3' flanking sequence of the identical microRNA, mir-16-1, and this mutation was not present in other strains, including the nearest neighbor, NZW. Levels of miR-16 were decreased in NZB lymphoid tissue. Exogenous miR-16 delivered to an NZB malignant B-1 cell line resulted in cell-cycle alterations and increased apoptosis. Linkage of the mir-15a/16-1 complex and the development of B-LPD in this spontaneous mouse model suggest that the altered expression of the mir-15a/16-1 is the molecular lesion in CLL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351108      PMCID: PMC1890829          DOI: 10.1182/blood-2007-02-071225

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  A uniform system for microRNA annotation.

Authors:  Victor Ambros; Bonnie Bartel; David P Bartel; Christopher B Burge; James C Carrington; Xuemei Chen; Gideon Dreyfuss; Sean R Eddy; Sam Griffiths-Jones; Mhairi Marshall; Marjori Matzke; Gary Ruvkun; Thomas Tuschl
Journal:  RNA       Date:  2003-03       Impact factor: 4.942

2.  Embryonic stem cell-specific MicroRNAs.

Authors:  Hristo B Houbaviy; Michael F Murray; Phillip A Sharp
Journal:  Dev Cell       Date:  2003-08       Impact factor: 12.270

Review 3.  Clinical staging and prognostic markers in chronic lymphocytic leukemia.

Authors:  Kanti R Rai; Tarun Wasil; Uzma Iqbal; Nancy Driscoll; Dilip Patel; Dale Janson; Bhoomi Mehrotra
Journal:  Hematol Oncol Clin North Am       Date:  2004-08       Impact factor: 3.722

Review 4.  Lymphocytes and lymphocyte functions in systemic lupus erythematosus.

Authors:  E S Raveche; A D Steinberg
Journal:  Semin Hematol       Date:  1979-10       Impact factor: 3.851

5.  Genetic studies in NZB mice. II. Hyperdiploidy in the spleen of NZB mice and their hybrids.

Authors:  E S Raveché; J H Tjio; A D Steinberg
Journal:  Cytogenet Cell Genet       Date:  1979

6.  A genetic map of the mouse with 4,006 simple sequence length polymorphisms.

Authors:  W F Dietrich; J C Miller; R G Steen; M Merchant; D Damron; R Nahf; A Gross; D C Joyce; M Wessel; R D Dredge
Journal:  Nat Genet       Date:  1994-06       Impact factor: 38.330

7.  Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities.

Authors:  G Juliusson; D G Oscier; M Fitchett; F M Ross; G Stockdill; M J Mackie; A C Parker; G L Castoldi; A Guneo; S Knuutila; E Elonen; G Gahrton
Journal:  N Engl J Med       Date:  1990-09-13       Impact factor: 91.245

8.  In vivo effects of hyperdiploid Ly-1+ B cells of NZB origin.

Authors:  E S Raveche; P Lalor; A Stall; J Conroy
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

9.  The NZB mouse as a model for chronic lymphocytic leukemia.

Authors:  J A Phillips; K Mehta; C Fernandez; E S Raveché
Journal:  Cancer Res       Date:  1992-01-15       Impact factor: 12.701

10.  A cultured malignant B-1 line serves as a model for Richter's syndrome.

Authors:  B Peng; D H Sherr; F Mahboudi; J Hardin; Y H Wu; L Sharer; E S Raveché
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

View more
  106 in total

Review 1.  Role of microRNAs in lymphoid biology and disease.

Authors:  Muller Fabbri; Carlo M Croce
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

2.  MicroRNA polymorphisms: a giant leap towards personalized medicine.

Authors:  Prasun J Mishra
Journal:  Per Med       Date:  2009-03-01       Impact factor: 2.512

Review 3.  miRNAs in normal and malignant B cells.

Authors:  Ai Kotani; Ratanakanit Harnprasopwat; Takae Toyoshima; Toyotaka Kawamata; Arinobu Tojo
Journal:  Int J Hematol       Date:  2010-07-08       Impact factor: 2.490

Review 4.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

Review 5.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

Review 6.  Causes and consequences of microRNA dysregulation.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

7.  Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance.

Authors:  Weixin Wang; Youn K Shim; Joel E Michalek; Emily Barber; Layla M Saleh; Byeong Yeob Choi; Chen-Pin Wang; Norma Ketchum; Rene Costello; Gerald E Marti; Robert F Vogt; Ola Landgren; Katherine R Calvo
Journal:  J Toxicol Environ Health A       Date:  2020-04-14

Review 8.  MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine.

Authors:  Prasun J Mishra; Joseph R Bertino
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

9.  Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer.

Authors:  Lin Zhang; Stefano Volinia; Tomas Bonome; George Adrian Calin; Joel Greshock; Nuo Yang; Chang-Gong Liu; Antonis Giannakakis; Pangiotis Alexiou; Kosei Hasegawa; Cameron N Johnstone; Molly S Megraw; Sarah Adams; Heini Lassus; Jia Huang; Sippy Kaur; Shun Liang; Praveen Sethupathy; Arto Leminen; Victor A Simossis; Raphael Sandaltzopoulos; Yoshio Naomoto; Dionyssios Katsaros; Phyllis A Gimotty; Angela DeMichele; Qihong Huang; Ralf Bützow; Anil K Rustgi; Barbara L Weber; Michael J Birrer; Artemis G Hatzigeorgiou; Carlo M Croce; George Coukos
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

10.  The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells.

Authors:  Huiwu Zhao; Anna Kalota; Shenghao Jin; Alan M Gewirtz
Journal:  Blood       Date:  2008-09-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.